REACH Registry

The REACH Registry is the first outpatient registry in the world to track actual event rates and treatment patterns in a broad range of patients with atherothrombosis. The registry follows more than 60,000 patients over four years, involving 44 countries and 5,000 investigators. The REACH registry aims to assess and treat patients with a history of coronary artery disease, cerebrovascular disease (stroke/TIA) or peripheral occlusive disease, as well as patients with a combination of serious risk factors. The REACH registry is sponsored by sanofi-aventis, Bristol-Myers Squibb and the Waksman Foundation (Tokyo, Japan), who were involved in the design, conduct and data collection of the study.